UNITED STATES
                       SECURITIES AND EXCHANGE COMMISSION
                             Washington, D.C. 20549

                                 --------------

                                  FORM 10-KSB/A

          |X| ANNUAL REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES
                              EXCHANGE ACT OF 1934

                  For the annual period ended December 31, 2004

        |_| TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES
                              EXCHANGE ACT OF 1934

              For the transition period from _________ to _________

                               SECURED DATA, INC.

                                 --------------

                 (Name of Small Business Issuer in Its Charter)

            NEVADA                   Commission File No:         87-0650264
(State or other jurisdiction of           000-32253           (I.R.S. Employer
incorporation or organization)                               Identification No.)

 16B/F Ruixin Road Bldg. No. 25 Gaoxin Road Xi An 710075 Shaanxi Province, China
                    (Address of principal executive offices)

                                (86) 29 8824 6358
                (Issuer's telephone number, including area code)

        Securities Registered Pursuant to Section 12(b) of the Act: None

           Securities Registered Pursuant to Section 12(g) of the Act:

                    Common Stock, Par Value $0.001 Per Share
                                (Title of Class)

      Check whether the issuer (1) filed all reports required to be filed by
Section 13 or 15(d) of the exchange Act during the past 12 months (or for such
shorter period that the registrant was required to file such reports); and (2)
has been subject to such filing requirements for the past 90 days.

      Yes |X|   No |_|

      Check if there is no disclosure of delinquent filers in response to Item
405 of Regulation S-B contained in this form, and no disclosure will be
contained, to the best of registrant's knowledge, in definite proxy or
information statements incorporated by reference in Part III of this form 10-KSB
or any amendment to this Form 10-KSB. |_|

      The issuer's revenues for the fiscal year ended December 31, 2004 were
$2,478,763.

      The aggregate market value of the common stock held by non-affiliates as
of March 31, 2005 was $2,874,187

      State the number of shares outstanding of each of the issuer's classes of
equity securities, as of the latest practicable date:

Title of Each Class of Equity                 Number of Shares Outstanding as of
Securities                                    December 31, 2004
------------------------------                ----------------------------------
Common Stock, $0.001 par value                39,604,958

      Transitional Small Business Disclosure Format (check one): Yes |_| No |X|


                                                                               i
<PAGE>

                                TABLE OF CONTENTS

<TABLE>
<CAPTION>
                                                                                                           Page
                                                                                                           ----
<S>         <C>                                                                                            <C>
PART I
            ITEM 1.   Description of Business
            ITEM 2.   Description of Properties
            ITEM 3.   Legal Proceedings
            ITEM 4.   Submission of Matters to a Vote of Security Holders
PART II
            ITEM 5.   Market for Common Equity and Related Stockholder Matters
            ITEM 6.   Management's Discussion and Analysis
            ITEM 7.   Financial Statements
            ITEM 8.   Changes in and Disagreements with Accountants on Accounting and Financial
                      Disclosures
            ITEM 8A.  Controls and Procedures
            ITEM 8B.  Other Information
PART III
            ITEM 9.   Directors, Executive Officers, Promoters and Control Persons, Compliance With
                      Section 16(A) of the Exchange Act
            ITEM 10.  Executive Compensation
            ITEM 11.  Security Ownership of Certain Beneficial Owners and Management
            ITEM 12.  Certain Relationships and Related Transactions
            ITEM 13.  Exhibits
            ITEM 14.  Principal Accounting Fees and Services
</TABLE>


                                                                              ii
<PAGE>

      This annual report contains certain forward-looking statements within the
meaning of Section 27A of the Securities Act of 1933, as amended, and Section
21E of the Securities Exchange Act of 1934, as amended. These include statements
about our expectations, beliefs, intentions or strategies for the future, which
we indicate by words or phrases such as "anticipate," "expect," "intend,"
"plan," "will," "we believe," "our company believes," "management believes" and
similar language. These forward-looking statements are based on our current
expectations and are subject to certain risks, uncertainties and assumptions,
including those set forth in the discussion under Item 1. Description of
Business" and Item 6. "Management's Discussion and Analysis", including under
the heading "- Risk Factors" under Item 6. Our actual results may differ
materially from results anticipated in these forward-looking statements. We base
our forward-looking statements on information currently available to us, and we
assume no obligation to update them. In addition, our historical financial
performance is not necessarily indicative of the results that may be expected in
the future and we believe that such comparisons cannot be relied upon as
indicators of future performance.

      Certain financial information included in this annual report has been
derived from data originally prepared in Renminbi (RMB), the currency of the
People's Republic of China. For purposes of this annual report, a conversion
rate of US$1.00 to RMB 8.3 was utilized. There is no assurance that RMB amounts
could have been or could be converted into US dollars at that rate.

      Secured Data, Inc., through its subsidiary Northwest BioTechnic Inc.
("NBTI") owns and operates, Huifeng Biochemistry Joint Stock Company
("Huifeng"), which is a joint venture company established under the laws of the
People's Republic of China ("PRC" or "China") with its main business as
production and sales of plant extracts, biochemical products and pharmaceutical
raw products in the PRC.

<PAGE>

                                     PART I

ITEM 1. DESCRIPTION OF BUSINESS

HISTORY

      Our company, Secured Data, Inc. ("we", "us", "our", "SCRE", the `Company"
or "our Company"), was incorporated under the laws of the State of Nevada and
trades on the Over the Counter ("OTC") Bulletin Board under the symbol "SCRE".

      Secured Data, Inc. is a corporation formed under the laws of the State of
Nevada on March 16, 2000. During the year 2000, we acquired a license to market
VitaMineralHerb.com products to customers in Oklahoma and New Mexico.
VitaMineralHerb.com hosts an Internet web site where health related products can
be purchased for resale; the web site then automatically credits the licensee
with purchases from their customers. We did not generate any revenues from the
above endeavors and during March 2002, we decided to terminate our involvement
with marketing vitamins and such related projects; consequently, we cancelled
our license agreement with VitaMineralHerb.com. Since October 2002, management's
business plan was to seek out a privately held business with whom the Company
can reorganize so as to take advantage of the Company's status as a publicly
held corporation.

      On December 20, 2004, in pursuant to the terms of a Stock Purchase
Agreement ("Malone Agreement"), Art Malone, Jr. ("Selling Shareholder") sold
7,229,601 shares of the common stock of Secured Data, Inc. ("Company") for
$300,000 (the "Sale") to Zhi Lan Wang and Jun Lin, individuals, on the closing
date of December 20, 2004. As a result, the 7,229,601 shares of the common stock
of the Company sold represented approximately 56.18% of the total outstanding
stock of the Company. Immediately thereafter, pursuant to the terms of an
Agreement and Plan of Reorganization dated December 20, 2004 ("Northwest
Agreement"), the Company initially purchased 30% of the common shares of
Northwest BioTechnic Inc. ("NBTI"), a British Virgin Islands corporation, in
exchange for 80,735,590 shares of the Company's common stock ("Acquisition").
The purchase price for the remaining 70% of NBTI's common shares was $1,900,000
payable by the Company's issuance of a promissory note ("Promissory Note") on
December 20, 2004 The Promissory Note may be convertible into 10,465,725 (post a
one for eighteen reverse split) shares of the Company's common stock. As a
result, the 80,735,590 shares of the common stock of the Company sold
represented approximately 86.3% of the total outstanding stock of the Company.
Upon conversion of the Promissory Note to common stock, the Company will have
sold approximately 95.4% of the total outstanding stock of the Company.

      NBTI was incorporated in the British Virgin Islands on June 25, 2004. NBTI
operates through its wholly owned subsidiary, Huifeng Biochemistry Joint Stock
Company ("Huifeng"), which is a joint venture company established under the laws
of the PRC and is a company engaged in the production and sales of plant
extracts, biochemical products and pharmaceutical raw products in the PRC. There
are no regulatory requirements or other governmental restrictions in the PRC
that materially affect the Company's operations, other than normal regulations
covering the production of medicinal products discussed under "Government
Regulations".

BUSINESS OVERVIEW

      SCRE, through its wholly owned subsidiary NBTI, owns 100% of Huifeng which
produces and sells plant extracts, biochemical products and pharmaceutical raw
products in the PRC. Huifeng was founded on January 18, 2000. With its
proprietary technology of "Producing Rutin by Eliminating Enzyme and Mucus"
together with abundant resources of high quality pagoda rice in the Northwest
region of China as raw material, Huifeng developed and specialized itself as one
of the major technology based Rutin company in Xian provinces within two years
after establishment. Huifeng possesses one of the most advanced and patented
Rutin-refined technologies and is a major Rutin supplier in world market.

<PAGE>

      During 2004 and 2003, 100% of the Company's assets were located in China
and 90% of the Company's revenues were derived from companies located in China.

      The Company relied on two customers, Shandong Dai Yu Pharmaceutical
Company Limited and Shanxi Hon Lok Company Limited, for an aggregate of
approximately 63% of sales for the year ended December 31, 2004. The Company
relied on three customers, Shandong Dai Yu Pharmaceutical Company Limited,
Shanxi Hon Lok Company Limited and Wan Tat Pharmaceutical Company Limited, for
an aggregate of approximately 58% of sales for the year ended December 31, 2003.

      The Company relied on four suppliers, Fengsheng Ren, Zhixiang Gao,
Yangling Ai and Feng Li for an aggregate of 62% of purchases for the year ended
December 31, 2004. The Company relied on three suppliers, Feng Li, Cungui Zhang
and Shuyuan Li for an aggregate of 72% of purchases for the year ended December
31, 2003.

      The technology for producing Rutin is accepted and audited by the State
Intellectual Property Bureau of PRC (Patent number: 02114402.8). This patent was
also published on the "Invention Patent Communique", volume 18, No 41. We own
all the patent rights and are the legal owners of such patent as granted by the
Chinese government.

      The extractive process of producing Rutin - "Producing Rutin by
Eliminating Enzyme and Mucus" is a patented technology with procedures as
follows: proprietary processes are used to purifying raw material by using
"Eliminating Enzyme". The extracts are further processed by another extraction
procedure through using "Eliminating Mucus" as extraction material. The
semi-finished product after the purification and extraction process will be
further processed by "Alkali Extraction" and "Acid Deposition" to obtain Rutin,
the product produced by us.

      Huifeng emphasized technology and product innovation and its strategic
mission is to commercialize Chinese traditional medicine. Our business missions
are:

      (a)   Obtain Good Manufacturing Practice (GMP) certification that is
            awarded by the State Food and Drug Administration Bureau of the PRC
            government for Huifeng's manufacturing facilities for medicine
            production;

      (b)   Building a raw material production site according to "GAP" standard,
            the certification standard for Chinese traditional medicine that was
            introduced and regulated by the State Food and Drug Administration
            Bureau of the PRC government that governs the production process to
            ensure quality in the production process;

      (c)   Building GLP standard, meaning "Medicine Quality System Regulation
            for Non-Clinic" that was introduced and regulated by the State Food
            and Drug Administration Bureau of the PRC government and
            consideredan international standard for laboratories for advanced
            function of biological molecules development and production; and

      (d)   Developing natural cosmetics, health food and beverage using Rutin
            as raw materials;

      To accomplish the mission set forth in (c) above, the existing physical
conditions of the Company's research laboratory needs substantial modifications,
including, but not limited to, an increase in the floor area of the laboratory,
renovation of the internal set up of the laboratory, the purchase of new
laboratory equipment, and to improve the environment to conduct research. It is
estimated that a minimum of $120,000 will be required for this modification and
the Company intends to implement it after raising funds for the Company,

OUR PRODUCTS

      Huifeng produces a series of Rutin and Rutin related products:

      Pharmaceutical Intermediates

                                     1.    NF11 Rutin (USP standard)
                                     2.    DAB8 DAB9 DAB10 DAB11 Rutin (German
                                           Codex Standard)
                                     3.    Troxerutin (farinaceous
                                           injectioniBoral application)
                                     4.    Quercetin, L-Rhamnone

<PAGE>

      Pharmaceutica Material         1.    Venoruton (farinaceous
                                           injectioniBoral application)
                                     2.    Rutin
                                     3.    Berberine Hydrochlorrde
                                     4.    Matrine

      Plant Extractive               1.    Hesperidin
                                     2.    Naringin
                                     3.    Epimedium Extract
                                     4.    Matrine
                                     5.    Pueraria
                                     6.    Siybun Marianum P.E

      The chemical name of Rutin is rue glycoside (Molecular formula:
C27H30O163H2O) and it is a kind of plant extract. It can inhibit platelet
aggregation and prevent thrombosis. It can also improve the permeability of
capillary vessel, and has the properties of:

            1.    Anti - inflammatory;

            2.    Decreasing blood pressure and fat; and

            3.    Mitigating cerebral hemorrhage.

      Also, it has positive effect in protecting heart and cerebral hemorrhage
and ischemia-reperfusion injury. It is widely used as raw material for heart and
cerebra blood vessel medicines as well as additive for cosmetic and functional
food. The improvement in living standards in China also stimulates the growth in
demand of functional food and natural cosmetics.

PRODUCTION FACILITIES

      In 2004 Huifeng has two major production facilities and the equipment
resources of each of the facilities are as follows:

      1.    Manufacturing plant located at NO 1,Huifeng Rd, Changwu, Xianyang:

            o     This production site is for refining and manufacturing of new
                  products

            o     Has a total of ten buildings including:

                  o     A two levels office building

                  o     A four levels staff building

                  o     Three manufacturing buildings (including extract
                        workshops, refining workshops and packaging workshops)

                  o     One raw materials storage building

                  o     One building for storage of finished products

                  o     One building for dangerous products

                  o     Building for power and maintenance (including boiler,
                        power distribution and maintenance)

                  o     One cafeteria and staff canteen

            o     The production capability of the plant is approximately 500
                  tons/year

      2.    Manufacturing plant located in Fenghui, Changan, Xian

            o     This production site is for extract and supplies raw materials
                  for refining

<PAGE>

            o     Has a total of four buildings including:

                  o     One office building

                  o     One manufacturing building (including extract workshops,
                        crystallization workshops, communication workshops and
                        packaging workshops),

                  o     One raw materials building

                  o     One boiler

            o     The production capacity of the plant is approximately 300
                  tons/year

      The two production facilities together occupy a total area of
approximately 300,000 square feet. The existing utilization rates of the two
plants are approximately 60% to70%. The general physical condition of the plants
and production facilities of the Company can completely satisfy the production
needs of the Company in terms of quantity and production quality for the near
future.

      Raw materials and ingredients, such as carbinol and hydrochloric acid that
are needed in the manufacturing or refining process during production of our
products, are dangerous chemicals that require special handling. Our building
for dangerous products is constructed according to the GMP standards. These raw
materials are stored separately in our building for dangerous products to avoid
or minimize dangers related to storage and applications of these special raw
materials and ingredients.

TARGET MARKETS AND PRINCIPAL CUSTOMERS

      All of Huifeng's products are raw materials for production of medicines
and the users of these products are industrial clients. As a result, Huifeng's
main target customers are pharmaceutical companies and food manufacturers.

      For the year ended December 31, 2004, $2,177,478 or 87.8% of our sale
revenues was derived from sales of Rutin and Rutin related Pharmaceutical
intermediates and material. $301,285 or 12.2% of our sales revenues was derived
from sales of plant extracts.

SALES AND MARKETING

      Since the majority of Huifeng's products are raw materials for production
of medicines and target customers are mostly industrial clients, Huifeng sells
and distributes its products mainly through direct selling to medicine and food
manufacturers. Usually customers will place purchase orders directly with the
sales and marketing team of Huifeng.

      Refined products and the refining process refers to the refining of raw
material into Rutin and Rutin itself is a raw material provided to other
pharmaceutical companies and food manufacturers, who are all customers of our
Company.

      The organization structure of the sales and marketing team of Huifeng is:
Sales director manages the whole sales team through sales managers and each of
the sales managers controls a team of sales supervisors and salesmen.

      Huifeng also participates in distribution and marketing activities that
aim at strengthening its ties with existing and new customers. One of the mostly
used techniques to expand its distribution network and develop new customers is
participating in various domestic and international medicine raw materials
exhibitions. Also, Huifeng focuses in improving the quality of products and
after-sale services in order to better maintain customer relationships.

<PAGE>

COMPETITION

      Huifeng engages in Rutin production in China. With its proprietary
technology of "Producing Rutin by Eliminating Enzyme and Mucus" and with
abundant resources of high quality pagoda rice in the Northwest region of China
as raw material, Huifeng has not faced substantial competition within China.
From time to time there are many small domestic Rutin manufacturers but these
companies will not impose a threat to Huifeng's business expansion in China.

      Based on similarity of products, pricing, and production scale, we believe
that the major competitor of Huifeng is Sichuan Xietong Pharmaceutical Company
Limited ("Xietong"). However, because of what we believe based on our search of
publicly available documents to be a lack of technological patents and access to
raw materials, we believe that Xietong is gradually fading out of the Rutin
refining business and is shifting its business from raw medicine production to
finished medicine production, and retains a rather small portion of its business
in raw medicine production. This information is based market information from
our customers and our sales and marketing team.

PRINCIPAL OFFICE

      Our principal office is located at FL16B, Ruixin Bldg, NO.25, Gaoxin Rd,
Xian China.

EMPLOYEES AND ORGANIZATION

As of December 31, 2004, Huifeng had approximately 186 full-time employees, out
of which approximately 75 are technicians. None of our employees are covered by
a collective bargaining agreement, we have never experienced a work stoppage,
and we consider our labor relations to be excellent.

      The organization of Huifeng is divided into 8 departments that are
supervised by our chief executive officer: personnel department, financial
department, securities department, sales department, provision department,
inspection department, production department and R&D department. The production
department supervises the two manufacturing plants and the raw material
production site.

BUSINESS DEVELOPMENT AND ACQUISITIONS

      In 2005 Huifeng will focus on

            1.    Increase the market share on Rutin in both the international
                  and domestic markets;

            2.    Commercialize additional one to two new products and strive to
                  launch these products into the public market; and

            3.    Enlarge the organization and improve the production
                  efficiency.

PATENTS AND INTELLECTUAL PROPERTIES

      Huifeng's proprietary technology "Producing Rutin by Eliminating Enzyme
and Mucus" received Chinese national technology patent with a 10 year protection
period.

      The patent system of China includes invention patents, practical patents
and shape patents. Patents granted under the Chinese patent system protect the
intellectual properties owned by the patent owner against infringement by third
parties. Patents obtained by our Company are protected only in the PRC. We have
not obtained any international patents.

      The technology we use in our manufacturing process (the extractive process
of producing Rutin), is "Producing Rutin by Eliminating Enzyme and Mucus". This
is a patented technology wherein proprietary processes are used to purify raw
material using "Eliminating Enzyme". The extracts are further processed by
another extraction procedure by using "Eliminating Mucus" as extraction
material. The semi-finished product after the purification and extraction
process will be further processed by "Alkali Extraction" and "Acid Deposition"
to obtain Rutin.

<PAGE>

GOVERNMENT REGULATIONS

            Chinese government requires all medicine and medicinal product
related manufacturers to obtain GMP certification on their pharmaceutical
manufacturing facilities. Huifeng obtained GMP certification from relevant
government regulatory on January 1, 2005.

      Chinese companies must follow a set of strict procedures before they can
engage in the pharmaceutical production businesses. First, they must apply for a
"certificate of incorporation" in the pharmaceutical business with the
Commercial and Industrial Registration Bureau. Then they must apply for a
"pharmaceutical production approval permit" and, before they can commence
operations to manufacture medical products, they must apply for GMP
certifications according to the "Ordinance for Medical Product Manufacturing"

      There are two ordinances governing the manufacturing of medical products
in China: (1) the Ordinance for the Management of Medicine, with a total of 111
articles governing safety issues in research, manufacture, sales and use of
medicine and medicinal products; and (2) the Ordinance for Medical Product
Manufacturing that governs the requirements in GMP certifications to regulate
the production environment, production facilities, production equipment,
production technologies and environment conservation issues related to the
production of medicine and medicinal products.

ITEM 2. DESCRIPTION OF PROPERTIES

      See "production facilities" in ITEM 1 - DESCRIPTION OF BUSINESS.

      There is no lien or encumbrance on any of the mentioned properties.

ITEM 3 LEGAL PROCEEDINGS

      We are currently not involved in any litigation that we believe could have
a material adverse effect on our financial condition or results of operations.
There is no action, suit, proceeding, inquiry or investigation before or by any
court, public board, government agency, self-regulatory organization or body
pending or, to the knowledge of the executive officers of our company or any of
our subsidiaries, threatened against or affecting our company, our common stock,
any of our subsidiaries or of our company's or our company's subsidiaries'
officers or directors in their capacities as such, in which an adverse decision
could have a material adverse effect.

ITEM 4 SUBMISSION OF MATTERS TO A VOTE OF SECURITY HOLDERS

      On March 23, 2005, the Board of Directors unanimously approved and
ratified an 1:18 reverse split (the "Reverse Split") of the Company's issued and
outstanding common stock and an amendment (the "Amendment") to its Articles of
Incorporation changing the name of the Company to "Huifeng Bio-pharmaceutical
Technology Inc.", subject to the approval of the Company's stockholders. The
record date established by the Board for purposes of determining the number of
outstanding shares of voting stock entitled to vote on the Reverse Split and the
Amendment was March 23, 2005 (the "Record Date"). On the Record Date,
stockholders owning 53,850,640 shares of Common Stock, or approximately 57.5% of
the issued and outstanding shares of Common Stock, approved the Reverse Split
and the Amendment by action taken without a meeting in accordance with Nevada
law. No further vote of our stockholders was required.

      As a result, the Company filed a preliminary information statement
pursuant to Section 14(c) of the Securities Exchange Act of 1934 on March 23,
2005 in connection with the approval by a majority of the stockholders of (i) an
amendment to its Articles of Incorporation effecting the Reverse Split and (ii)
the Amendment

<PAGE>

      On the effective date of the Reverse Split the number of issued and
outstanding shares of common stock of the Company will be reduced from a total
of 93,604,958 shares which were outstanding on the Record Date, to approximately
5,200,275 shares.

      When filed with the Nevada Secretary of State, the Amendment will change
the name of the Company to "Huifeng Bio-pharmaceutical Technology Inc."

      However as of the date of this filing, this preliminary information
statement was still not approved by the Securities and Exchange Commission.

                                     PART II

ITEM 5 MARKET FOR COMMON EQUITY AND RELATED STOCKHOLDER MATTERS

      Our common stock is quoted on the Over-the-Counter Bulletin Board
("OTCBB") under the symbol "SCRE".

      Trading in our common stock has been limited and sporadic. The following
table shows the range of high and low bid quotations reported by the OTCBB in
each fiscal quarter from January 1, 2003 to December 31, 2004, and the
subsequent interim period. The OTCBB quotations reflect inter-dealer prices,
without retail mark-up, mark-down or commission, and may not represent actual
transactions. As of June 17, 2005, there were approximately 80 holders of record
of our common stock. This number does not include an indeterminate number of
shareholders whose shares are held by brokers in street name.

BID PRICES FOR THE REPORTING PERIOD

    Year                      Period                        High           Low
    ----                      ------                        ----           ---

    2003       First Quarter                               $0.040        $0.005
               Second Quarter                              $0.040        $0.010
               Third Quarter                               $0.015        $0.010
               Fourth quarter                              $0.020        $0.000

    2004       First Quarter                               $0.300        $0.010
               Second Quarter                              $0.070        $0.060
               Third Quarter                               $0.300        $0.050
               Fourth quarter                              $0.590        $0.020

    2005       First Quarter                               $0.160        $0.050
               Second Quarter (through June 17, 2005)      $0.100        $0.050

DIVIDENDS

      We presently intend to retain future earnings, if any, to provide funds
for use in the operation and expansion of our business. Accordingly, we have not
declared or paid any dividends to our common shareholders and do not presently
intend to do so. Any future decision whether to pay dividends will depend on our
financial condition and any other factors that our Board of Directors deems
relevant.

ISSUANCE OF SHARES

      During the three month period ended June 30, 2004 the Company issued
6,232,290 shares of its common stock to Art Malone Jr. as repayment for his cash
advances to the Company that was used to operate the business of the Company.

<PAGE>

      Between December 15, 2004 and December 20, 2004, the Company issued a
total of 585,000 shares of common stock to three creditors in exchange for
satisfaction and settlement of Company debts totaling $93,000.

      On December 20, 2004, the Company issued 80,735,590 shares of common stock
to the shareholders of NBTI in pursuant to the Acquisition as described in the
Section "History" of "ITEM 1 - DESCRIPTION OF BUSINESS"

      Unless otherwise noted, the sales set forth above involved no
underwriter's discounts or commissions and are claimed to be exempt from
registration with the Securities and Exchange Commission pursuant to Section 4
(2) of the Securities Act of 1933, as amended, as transactions by an issuer not
involving a public offering, the issuance and sale by the Company of shares of
its common stock to financially sophisticated individuals who are fully aware of
the Company's activities, as well as its business and financial condition, and
who acquired said securities for investment purposes and understood the
ramifications of same.

ITEM 6 MANAGEMENT'S DISCUSSIONS AND ANALYSIS

      This annual report contains forward-looking statements within the meaning
of the federal securities laws. These include statements about our expectations,
beliefs, intentions or strategies for the future, which we indicate by words or
phrases such as "anticipate," "expect," "intend," "plan," "will," "we believe,"
"SCRE believes," "management believes" and similar language. The forward-looking
statements are based on the current expectations of SCRE and are subject to
certain risks, uncertainties and assumptions, including those set forth in the
discussion under "Description of Business" and "Management's Discussion and
Analysis or Plan of Operation,". The actual results may differ materially from
results anticipated in these forward-looking statements. We base the
forward-looking statements on information currently available to us, and we
assume no obligation to update them.

      On December 20, 2004, pursuant to the Malone Agreement, Art Malone, Jr.
("Selling Shareholder") sold 7,229,601 shares of the common stock of the Company
for $300,000 (the "Sale") to Zhi Lan Wang and Jun Lin, individuals on the
closing date of December 20, 2004. As a result, the 7,229,601 shares of the
common stock of the Company sold represented approximately 56.18% of the total
outstanding stock of the Company. Immediately thereafter, On December 20, 2004
SCRE completed a Northwest Agreement, of which the Company initially purchased
30% of the common shares of NBTI in exchange for 80,735,590 shares of the
Company's common stock ("Acquisition"). The purchase price for the remaining 70%
of NBTI's common shares was $1,900,000 payable by the Company's issuance of a
promissory note ("Promissory Note") on December 20, 2004 The Promissory Note may
be convertible into 10,465,725 (post a one for eighteen reverse split) shares of
the Company's common stock. As a result, the 80,735,590 shares of the common
stock of the Company sold represented approximately 86.3% of the total
outstanding stock of the Company. The Exchange resulted in a change of voting
control of the Company. Upon conversion of the Promissory Note to common stock,
the Company will have sold approximately 95.4% of the total outstanding stock of
the Company.

      NBTI was incorporated in the British Virgin Islands on June 25, 2004. NBTI
operates through its wholly owned subsidiary, Huifeng Biochemistry Joint Stock
Company ("Huifeng"), which is a joint venture company established under the laws
of China and is engaged in the production and sales of plant extracts,
biochemical products and pharmaceutical raw products in the PRC.

      The exchange was treated as a reverse acquisition for accounting purposes.
As such, the financial information reflected activity subsequent to the
acquisition for SCRE and its subsidiaries and financial activity of NBTI prior
to the acquisition. We will continue the business operations conducted by NBTI.

<PAGE>

CRITICAL ACCOUNTING POLICIES AND ESTIMATES

      We have identified one policy area as critical to the understanding of our
consolidated financial statements. The preparation of our consolidated financial
statements requires management to make estimates and assumptions that affect the
reported amounts of assets and liabilities and disclosure of contingent assets
and liabilities at the date of the consolidated financial statements and the
reported amounts of sales and expenses during the reporting periods. With
respect to net realizable value of the Company's accounts receivable and
inventories, significant estimation judgments are made and actual results could
differ materially from these estimates.

      The Company does not have any reserves against its accounts receivable or
inventories at December 31, 2004 and 2003. Management's estimation that there
are no reserves is based on the current facts that there is no significant aged
accounts receivable and the current inventory turnover is sufficient to realize
the current carrying value of the inventories. In making their judgment,
management has assumed that there will be continued demand for their products in
the future, thereby maintaining adequate turnover of the inventories.
Additionally, management has assumed that customers will continue to pay their
outstanding invoices timely, and that their customers' financial position will
not deteriorate significantly in the future, which would result in their
inability to pay their debts to the Company. While the Company's management
currently believes that there is little likelihood that the actual results of
their current estimates will differ materially from its current estimates, if
customer demand for its products decreases significantly in the near future, or
if the financial position of its customers deteriorates in the near future, the
Company could realize significant write downs for slow moving inventories or
uncollectible accounts receivable.

      We believe the following is among the most critical accounting policies
that impact our consolidated financial statements. We suggest that our
significant accounting policies, as described in our consolidated financial
statements in the Summary of Significant Accounting Policies, be read in
conjunction with this Management's discussion and Analysis of Financial
Condition and Results of Operations.

      We recognize revenue in accordance with Staff Accounting Bulletin ("SAB")
No. 104. All of the following criteria must exist in order for us to recognize
revenue:

      1.    Persuasive evidence of an arrangement exists;

      2.    Delivery has occurred or services have been rendered;

      3.    The seller's price to the buyer is fixed or determinable and

      4.    Collectibility is reasonably assured.

      The majority of the Company's revenue results from sales contracts with
distributors and revenue is generated upon the shipment of goods. The Company's
pricing structure is fixed and there are no rebate or discount programs.
Management conducts credit background checks for new customers as a means to
reduce the subjectivity of assuring collectibility. Based on these factors, the
Company believes that it can apply the provisions of SAB 104 with minimal
subjectivity.

RESULTS OF OPERATIONS

      The following table sets forth selected statement of operations data as a
percentage of revenues for the periods indicated.

                                                   Year Ended         Year Ended
                                            December 31, 2004  December 31, 2003
                                            -----------------  -----------------

      Revenues                                        100.00%              100%
      Cost of Revenues                                (90.17%)          (95.47%)
      Gross Margin                                      9.83%             4.53%
      General and administrative expenses             (16.76%)           (5.83%)
      Selling and distribution expenses                (1.68%)           (6.96%)
      Depreciation and amortization                    (0.36%)           (0.77%)
      Equity in loss of affiliate                      (0.00%)              --
      Interest income, net                              0.05%             7.23%
      Other income, net                                 0.03%             0.04%
      Income tax expenses                              (0.30%)              --
      Minority interest                                 0.34%             0.92%
      Net Loss                                         (8.86%)           (0.84%)

<PAGE>

YEAR ENDED DECEMBER 31, 2004 COMPARED TO YEAR ENDED DECEMBER 31, 2003

Revenues, Cost of Revenues and Gross Margin

      Revenues for the year ended December 31, 2004 were $2,478,763 an increase
of $1,762,904 from $715,859 for the year ended December 31, 2003. Our increases
in sales revenues in 2004 were mainly attributable to the increase in our sales
of Rutin related products. The increase in demand for Rutin related products in
China created a substantial market for Rutin and resulted in increased in sales
of our Rutin products in 2004.

      Cost of revenues for the year ended December 31, 2004 were $2,235,189, an
increase of $1,551,759 from $683,430 for the year ended December 31, 2003.
Compared to the year ended December 31, 2003, the increase in cost of sales of
our products was because of our increase in sales revenue in 2004. However, the
increase in cost of sales of our products was not in the same proportion as our
increase in sales revenue because our profit margin improved in 2004 as compared
to 2003.

      Our gross profit margin for 2004 improved from 4.53% in 2003 to 9.83% in
2004 as a result of our improved efficiency in production due to economy of
scale of production as sales volume increased.

      Gross margin for the year ended December 31, 2004 was $243,574, an
increase of $211,145 from $32,429 for the year ended December 31, 2003.

General and Administrative Expenses

      General and Administrative expenses totaled $ 415,342 for the year ended
December 31, 2004, an increase of $ 373,613 from $41,729 for the year ended
December 31, 2003. The increase in general and administrative expenses was
mainly due to an increase of $353,613 in general and administrative expenses in
Huifeng. The increase in general and administrative expenses in Huifeng was due
to an increase of $5,455 in salary expenses and $151,187 in office overhead as a
result of increased business activities. There were also one-time expenses of
$118,836 for factory relocation expenses and $78,135 for a special audit of
Huifeng. There were also $20,000 in expenses related to the Malone Agreement,
the Northwest Agreement and the Acquisition, which were all one-time events in
2004.

Selling and Distribution Expenses

      Selling and distribution expenses totaled $41,569 for the year ended
December 31, 2004, a decrease of $8,264 from $49,833 for the year ended December
31, 2003. Compared to the same year ended December 31, 2003, we increased $3,841
and $16,662 in salary expenses and overhead, respectively, for sales and
marketing staffs as a result of increase in number of employee. However, we
reduced our expenses on promotion material of $28,767 because in the same year
ended 2003, we incurred an one off expenses of purchase of promotion material
that was not repeated in 2004. The Company had not increased its expenses in
sales and distribution despite sales revenue increased, as most of the Company
sales in 2004 were direct selling to industrial customers that did not rely on
intensive sales and distribution activities.

Liquidity and Capital Resources

Cash

      Our cash balance amounted to $167,511 at December 31, 2004.

<PAGE>

In the year ended December 31, 2004, our cash used in operating activities
amounted to $ 526,363, mainly to due the net loss in the current year amounted
to $ 219,730. Also, in the current year, inventories and other receivables
increased by $405,019 and $236,920, respectively as a result of increased in
business activities. We experienced increase in inventory level in 2004 as a
result of increased in production scale to capture economy of scale in
production to improve profit margin as well as stock up on raw material to
reduce raw material cost and as a result, or percentage profit margin improved
from 4.53% in 2003 to 9.83% in 2004. We also experienced increase in accounts
receivable as a result of increase in sales of which a portion of our increased
sales revenues were from credit sales.

      In the year ended December 31, 2004, cash flow from investing activities
amounted to $35,642. Cash flow from financing activities amounted to $562,429,
mainly due to a decrease in amounts due from shareholders of $569,717, an
increase in amounts owed to stockholders of $184,354, and offset by a decrease
in notes payable.

      The Company is currently funding its operations from, in addition to sales
revenues, loans from shareholders.

      For the year ended December 31, 2004, our Company recorded a net loss of
$219,730. However, among the general and administrative expenses of $415,342,
there were one off expenses of $118,836 for factory relocation expenses and
$78,135 for special audit in Huifeng. Our net loss should narrow down to $22,759
should one time expenses for 2004 did not occur. Also, there was a total of
$94,097 non cash depreciation and amortization expenses for the year ended 2004,
which had no impact on our cash flow. With anticipated increase in sales revenue
in 2005, we believe that the Company should be able to generate positive cash
flow from operations in the operating company level in PRC to support the
on-going operations of the Company. Increase in sales revenue in future together
with our existing cash and cash equivalents balance of $167,511 as of December
31, 2005, we anticipate that it will be sufficient to support the expenditure of
the Company for the next 12 months for the purpose of continuous operations"

Working Capital

      Our working capital deficit amounted to $342,854 at December 31, 2004.
However, our current liabilities in year ended 2004 included a promissory note
of $1,900,000, of which should it be exercised by the bearer, would reduce our
current liabilities from $ 2,314,085 to $414,085 and our working capital should
increase to a surplus of $1,557,146. So, we believe that our existing working
capital level should be able to support the on going operations of the Company
at its current activities level.

NEW ACCOUNTING PRONOUNCEMENTS

      In January 2003, (as revised in December 2003) The Financial Accounting
Standards Board ("FASB") issued Interpretation No. 46(R), "Consolidation of
Variable Interest Entities", an interpretation of Accounting Research Bulletin
("ARB") No. 51, "Consolidated Financial Statements". Interpretation No. 46(R)
addresses consolidation by business enterprises of variable interest entities,
which have one or both of the following characteristics: (i) the equity
investment at risk is not sufficient to permit the entity to finance its
activities without additional subordinated support from other parties, which is
provided through other interest that will absorb some or all of the expected
losses of the entity; (ii) the equity investors lack one or more of the
following essential characteristics of a controlling financial interest: the
direct or indirect ability to make decisions about the entities activities
through voting rights or similar rights; or the obligation to absorb the
expected losses of the entity if they occur, which makes it possible for the
entity to finance its activities; the right to receive the expected residual
returns of the entity if they occur, which is the compensation for the risk of
absorbing the expected losses.

      Interpretation No. 46(R), as revised, also requires expanded disclosures
by the primary beneficiary (as defined) of a variable interest entity and by an
enterprise that holds a significant variable interest in a variable interest
entity but is not the primary beneficiary. Interpretation No. 46(R), as revised,
applies to small business issuers no later than the end of the first reporting
period that ends after December 15, 2004.

<PAGE>

      This effective date includes those entities to which Interpretation 46 had
previously been applied. However, prior to the required application of
Interpretation No. 46(R), a public entity that is a small business issuer shall
apply Interpretation 46 or this Interpretation to those entities that are
considered to be special-purpose entities no later than as of the end of the
first reporting period that ends after December 15, 2003.

      Interpretation No. 46(R) may be applied prospectively with a
cumulative-effect adjustment as of the date on which it is first applied or by
restating previously issued financial statements for one or more years with a
cumulative-effect adjustment as of the beginning of the first year restated.

      In May 2003, the FASB issued SFAS No. 150, "Accounting For Certain
Financial Instruments with Characteristics of both Liabilities and Equity". SFAS
No. 150 changes the accounting for certain financial instruments with
characteristics of both liabilities and equity that, under previous
pronouncements, issuers could account for as equity. The new accounting guidance
contained in SFAS No. 150 requires that those instruments be classified as
liabilities in the balance sheet.

      SFAS No. 150 affects the issuer's accounting for three types of
freestanding financial instruments. One type is mandatorily redeemable shares,
which the issuing company is obligated to buy back in exchange for cash or other
assets. A second type includes put options and forward purchase contracts, which
involves instruments that do or may require the issuer to buy back some of its
shares in exchange for cash or other assets. The third type of instruments that
are liabilities under this Statement is obligations that can be settled with
shares, the monetary value of which is fixed, tied solely or predominantly to a
variable such as a market index, or varies inversely with the value of the
issuers' shares. SFAS No. 150 does not apply to features embedded in a financial
instrument that is not a derivative in its entirety.

      Most of the provisions of SFAS 150 are consistent with the existing
definition of liabilities in FASB Concepts Statement No. 6, "Elements of
Financial Statements". The remaining provisions of this Statement are consistent
with the FASB's proposal to revise that definition to encompass certain
obligations that a reporting entity can or must settle by issuing its own
shares. This Statement shall be effective for financial instruments entered into
or modified after May 31, 2003 and otherwise shall be effective at the beginning
of the first interim period beginning after June 15, 2003, except for
mandatorily redeemable financial instruments of a non-public entity, as to which
the effective date is for fiscal periods beginning after December 15, 2004.

      In November 2004, the FASB issued SFAS No. 151 "Inventory Costs". This
statement amends the guidance in ARB No. 43, Chapter 4, "Inventory Pricing," to
clarify the accounting for abnormal amounts of idle facility expense, freight,
handling costs, and wasted material (spoilage). In addition, this Statement
requires that allocation of fixed production overhead to the costs of conversion
be based on the normal capacity of the production facilities. The provisions of
this Statement will be effective for the Company beginning in 2005.

      In December 2004, the FASB issued SFAS No. 153, "Exchanges of Non-Monetary
Assets, an Amendment of Accounting Principles Board ("APB") No. 29". This
statement amends APB Opinion No. 29, "Accounting for Nonmonetary Transactions".
Earlier guidance had been based on the principle that exchanges of nonmonetary
assets should be based on the fair value of the assets exchanged and APB No. 29
included certain exceptions to this principle. However, FASB 153 eliminated the
specific exceptions for nonmonetary exchanges with a general exception rule for
all exchanges of nonmonetary assets that do not have commercial and economic
substance. A nonmonetary exchange has commercial substance only if the future
cash flows of the entity is excepted to change significantly as a result of the
exchange. This statement is effective for nonmonetary exchanges occurring in
fiscal periods beginning after June 15, 2005.

      In December 2004, the FASB issued a revised SFAS No. 123, Accounting for
Stock-Based Compensation, which supersedes APB opinion No. 25, Accounting for
Stock Issued to Employees, and its related implementation guidance. This
statement requires a public entity to recognize and measure the cost of employee
services it receives in exchange for an award of equity instruments based on the
grant-date fair value of the award (with limited exceptions). These costs will
be recognized over the period during which an employee is required to provide
service in exchange for the award - the requisite service period (usually the
vesting period). This statement also establishes the standards for the
accounting treatment of these share-based payment transactions in which an
entity exchanges its equity instruments for goods or services. It addresses
transactions in which an entity incurs liabilities in exchange for goods or
services that are based on the fair value of the entity's equity instruments or
that may be settled by the issuance of those equity instruments. This statement
shall be effective the first interim or annual reporting period that begins
after December 15, 2005 for small business public entities and nonpublic
companies.

<PAGE>

      The implementations of the above pronouncements are not expected to have a
significant effect on the Company's consolidated financial statement
presentation or disclosure.

INFLATION

      Inflation has not had a material impact on our business.

CURRENCY EXCHANGE FLUCTUATIONS

      All of the Company's revenues and a majority of the expenses in 2004 were
denominated primarily in Renminbi ("RMB"), the currency of China. There can be
no assurance that RMB-to-U.S. dollar exchange rates will remain stable. A
devaluation of RMB relative to the U.S. dollar would adversely affect our
business, financial condition and results of operations. We do not engage in
currency hedging.

ITEM 7 FINANCIAL STATEMENTS

      The financial statements, together with the independent auditors' report
thereon, appears beginning on page F-1 of this report

ITEM 8 CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL
       DISCLOSURES

      There was no change in our certifying accountant for the period of January
1, 2004 to December 31, 2004.

      On March 14, 2005, the accounting firm of Jimmy C. H. Cheung & Co.,
Certified Public Accountants (a member of Kreston International), 304 Dominion
Centre, 43 Queen's Road East, Hong Kong, was engaged to take over the audit
responsibilities from Epstein Weber & Conover, PLC, certified public accountant;
and Epstein Weber & Conover, PLC was dismissed on that same date.

      During the Company's two most recent fiscal years and any subsequent
interim period prior to the engagement of Jimmy C. H. Cheung & Co., Certified
Public Accountants, the Company has not consulted with Jimmy C. H. Cheung & Co.,
Certified Public Accountants, or any other auditor, regarding any accounting or
audit concerns, to include, but not by way of limitation, those stated in Item
304(a)(2) of Regulation S-B.

      During the Company's two most recent fiscal years and the subsequent
interim period through the date of dismissal, the Company is not aware of any
disagreements with its former accountant, whether resolved or not resolved, on
any matter of accounting principals or practices, financial statement
disclosure, or auditing scope or procedure, which, if not resolved to said
accountants' satisfaction, would have caused it to make reference to the subject
matter of the disagreements(s) in connection with its report.

ITEM 8A CONTROLS AND PROCEDURES

      The Company maintains disclosure controls and procedures that are designed
to ensure that information required to be disclosed in the Company's Exchange
Act reports is recorded, processed, summarized and reported within the time
periods specified in the SEC's rules and forms, and that such information is
accumulated and communicated to the Company's management, including its Chief
Executive Officer and Chief Financial Officer, as appropriate, to allow timely
decisions regarding required disclosure based closely on the definition of
"disclosure controls and procedures" in Rule 13a-15(c). The Company's disclosure

<PAGE>

controls and procedures are designed to provide a reasonable level of assurance
of reaching the Company's desired disclosure control objectives. In designing
and evaluating the disclosure controls and procedures, management recognized
that any controls and procedures, no matter how well designed and operated, can
provide only reasonable assurance of achieving the desired control objectives,
and management necessarily was required to apply its judgment in evaluating the
cost-benefit relationship of possible controls and procedures. The Company's
certifying officer has concluded that the Company's disclosure controls and
procedures are effective in reaching that level of assurance.

         As of the end of the period of this report, the Company carried out an
evaluation, under the supervision and with the participation of the Company's
management, including the Company's Chief Executive Officer and the Company's
Chief Financial Officer, of the effectiveness of the design and operation of the
Company's disclosure controls and procedures. Based on the foregoing, the
Company's Chief Executive Officer and Chief Financial Officer concluded that the
Company's disclosure controls and procedures were effective.

      ITEM 8B OTHER INFORMATION

      Not applicable.

                                    PART III

ITEM 9 DIRECTORS, EXECUTIVE OFFICERS, PROMOTERS AND CONTROL PERSONS, COMPLIANCE
       WITH SECTION 16(A) OF THE EXCHANGE ACT

The following table sets forth the names and ages of our current directors and
executive officers, their principal offices and positions and the date each such
person became a director or executive officer of our company. Our executive
officers are elected annually by the Board of Directors. Our directors serve one
year terms until their successors are elected. The executive officers serve
terms of one year or until their death, resignation or removal by the Board of
Directors. There are no family relationships between any of the directors and
executive officers. In addition, there were no arrangements or understanding
between any executive officer and any other person pursuant to which any person
was selected as an executive officer. Currently, directors are not compensated
for serving on the Board of Directors. We have not established compensation or
executive committees. Currently, our entire board of directors serves as our
audit committee. Because of the small size of the Company and the risk attendant
to a small public company, we are currently unable to attract an audit committee
financial expert to our Board of Directors.

RESIGNATION OF DIRECTOR

      On December 20, 2004, subsequent to the Acquisition described in the
Section "History" of "ITEM 1 - DESCRIPTION OF BUSINESS", Art Malone, Jr.
resigned as the Company's Chief Executive Officer, Chief Financial Officer and
any other officer capacity. Mr. Malone resigned as a Director of the Company on
January 28, 2005.

      The resignations were not the result of any known disagreements with the
Company on any matter relating to the Company's operations, policies or
practices.

APPOINTMENT OF NEW DIRECTORS

      The Board of Directors, effective upon Mr. Malone's resignation on
December 20, 2004, appointed Jingan Wang as Chief Executive Officer and
President, Sanding Tao as Chief Financial Officer, and Xinwen Hou as Secretary
and a Director. The Board of Directors appointed the following persons to fill
the vacancies on the Board created by the resignations of the previous
directors:

      Jingan Wang
      Sanding Tao
      JunqiZhang

<PAGE>

BIOGRAPHIES OF OFFICERS AND DIRECTORS

Jingan Wang

      Mr. Jingan Wang, age 44, Chief Executive Officer of the Company, is the
founder and currently serves as President of Huifeng. Mr. Wang has over fifteen
years of experience in accounting and financial management area. Mr. Wang has
served as Accounting Supervisors and Chief Financial Officers for various
companies during his professional career. Before Mr. Wang founded Huifeng in
2000, he was the Chief Financial Officer for Wei Xing Enterprises from 1999 to
2000. Wei Xing Enterprises engages in the pharmaceutical business. Mr. Wang is
also a certified public accountant.

      Sanding Tao

      Mr. Sanding Tao, age 36, Chief Financial Officer of the Company and of
Huifeng. Mr. Tao served as VP of Finance and CFO for various technology and
bio-tech firms before he joined Huifeng in 2003. From 1998 - 2000, Mr. Tao
served as Chief Financial Officer for Xian Lan Xi Science & Technology Inc.; and
from 2000 -2003, Mr. Tao served as Chief Financial Officer for Xian Xing Yi
Science & Technology Inc. Xian Lan Xi Science & Technology Inc. engages in the
ambulance modification business. Xian Xing Yi Science & Technology Inc. is a
trading company specializing in medical instruments. Mr. Tao is a graduate of
Chinese Southern Financial College.

Xinwen Hou

      Mr. Xinwen Hou, age 36,Director and Secretary of the Company, currently
also serves as Assistant to the President and as Company Secretary for Huifeng
Biochemistry Joint Stock Company ("Huifeng") in Xian, China. Mr. Hou held
various leadership positions in different public companies in China before he
joined Huifeng in January 2004. From 1997 - 2003, Mr. Hou served as Company
Secretary for De Li Bang Pharmaceutical Inc., which is listed on China's A share
stock exchange. He is also a reputable economist. He graduated from Xian
Transportation University with a major in Business Administration.

      The following table summarizes the information of the directors and
executive officers of our Company:

Name                 Position                                Date Of Appointment
----                 --------                                -------------------
Jingan Wang          Chief Executive Officer                 December 20, 2004
Sanding Tao          Chief Financial Officer                 December 20, 2004
Xinwen Hou           Director and Secretary                  December 20, 2004

INDEMNIFICATION OF DIRECTORS AND OFFICERS

      Our articles of incorporation limit the liability of directors to the
maximum extent permitted by Nevada law. This limitation of liability is subject
to exceptions including intentional misconduct, obtaining an improper personal
benefit and abdication or reckless disregard of director duties. Our articles of
incorporation and bylaws provide that we may indemnify its directors, officer,
employees and other agents to the fullest extent permitted by law. Our bylaws
also permit us to secure insurance on behalf of any officer, director, employee
or other agent for any liability arising out of his or her actions in such
capacity, regardless of whether the bylaws would permit indemnification. We
currently do not have such an insurance policy.

<PAGE>

      Insofar as indemnification for liabilities arising under the Securities
Act of 1933 may be permitted for our directors, officers and controlling 1934
persons pursuant to the foregoing provisions, or otherwise, we have been advised
that in the opinion of the Securities and Exchange Commission such
indemnification is against public policy as expressed in the Securities Act and
is, therefore, unenforceable.

      CODE OF ETHICS

      We have recently adopted a Code of Ethics and Business Conduct authorizing
the establishment of a committee to ensure that our disclosure controls and
procedures remain effective. Our Code also defines the standard of conduct
expected by our officers, directors and employees. The Code is attached as an
exhibit to this report.

ITEM 10. EXECUTIVE COMPENSATION

      The executives of the Company received no compensation from the Company
for the fiscal year ending December 31, 2004. The Company currently has no
agreements for compensation of its executive, and has no stock option plan or
other equity compensation plan for its employees.

ITEM 11. SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT

      The following table sets forth certain information regarding beneficial
ownership of common stock as of June 15, 2005 by each person known to us to own
beneficially more than 5% of our common stock, each of our directors, each of
our named executive officers; and all executive officers and directors as a
group.

Name                    Position Held                   Shares Owned     % Owned
----                    -------------                   ------------     -------

Jingan Wang             Chief Executive Officer           37,299,843      39.85%
Sanding Tao             Chief Financial Officer            3,633,102       3.88%

Xinwen Hou              Director and Secretary             3,633,102       3.88%
Xian Renfeng Investment Ltd. Co.                           9,284,593       9.92%

All directors and executive officers as a group           44,566,047      47.61%

      The following table sets forth certain information regarding beneficial
      ownership of common stock as of June 15, 2005 by each person known to us
      to own beneficially more than 5% of our common stock, each of our
      directors, each of our named executive officers; and all executive
      officers and directors as a group assuming the conversion of the
      $1,900,000 Promissory Note into 10,465,725 shares of post 18 for 1 reverse
      split common stock.

Name                    Position Held                   Shares Owned     % Owned
----                    -------------                   ------------     -------

Jingan Wang             Chief Executive Officer            7,305,074      46.63%
Sanding Tao             Chief Financial Officer              201,839       1.29%
Xinwen Hou              Director and Secretary             1,248,412       7.97%
Zhang Junqi                                                1,046,573       6.68%
Wang Bijun                                                 1,046,573       6.68%
Wang Zhilan                                                1,046,573      6.68.%
Wang Xugang                                                1,046,573       6.68%

All directors and executive officers as a group            8,755,325      55.89%

<PAGE>

ITEM 12. CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS

      The Company borrowed funds from Art Malone, Jr., its former sole officer
and director for payment of operating expenses. As a result, during the three
month period ended June 30, 2004 the Company issued 6,232,290 shares of its
common stock to him as repayment for his cash advances and reimbursement for his
services that had accumulated to an amount of approximately $350,000.

      During the three month period ended September 30, 2004, the Company
borrowed an additional $9,600 from Art Malone, Jr. Subsequent to the Acquisition
described in the Section "History" of "ITEM 1 - DESCRIPTION OF BUSINESS", Art
Malone, Jr. waived his claims on the $9,600 loan to the Company.

            The Company had advanced funds totaling $62,493 and $632,210 to
stockholders as of December 31, 2004 and 2003 respectively as short-term,
unsecured loans free of interest payment.

The details of the short-term, interest free loans granted to individuals as of
December 31, 2003 and 2004 were as follows:

As of December 31, 2004

<TABLE>
<CAPTION>
Name of individual       Amount      Business purpose       Balance as of June      Payment terms
                                                                      13, 2005
--------------------------------------------------------------------------------------------------------------
<S>                      <C>         <C>                                <C>         <C>
Qiang Wang               21,963      Advance: material purchase             --      Repaid

Bijun Wang                1,950      Advance: material purchase             --      Repaid

Xugang Wang              10,692      Advance: material purchase             --      Repaid

Gaishi Wang               2,175      Advance: material purchase             --      Repaid

Penghui Fan                 783      Advance: material purchase            783      Repay upon end of business
                                                                                    trip
Yushan Li                   479      Advance: business trip                479      Repay upon end of business
                                                                                    trip
Kangrang Ma                  74      Advance: business trip                 --      Repaid

Guochao Zhi                 298      Advance: business trip                 --      Repaid

Cunpu Ma                  1,207      Advance: business trip              1,207      Repay upon end of business
                                                                                    trip
Guozhen Shang             1,140      Advance: business trip              1,140      Repay upon end of business
                                                                                    trip
Bijun Wang                4,831      Advance: material purchase          4,831      Repay upon complete of
                                                                                    purchase
Gengmin Tian              6,818      Advance: business trip              6,818      Repay upon end of business
                                                                                    trip
Xiaogang Zhang           10,083      Advance: business trip             10,083      Repay upon end of business
                                                                                    trip
</TABLE>

As of December 31, 2003

<TABLE>
<CAPTION>
Name of individual        Amount      Business purpose      Balance as of June      Payment terms
                                                                      13, 2005
--------------------------------------------------------------------------------------------------------------
<S>                      <C>          <C>                                   <C>     <C>
Qiang Wang                15,991      Advance: material purchase            --      Repaid
Bijun Wang                10,976      Advance: material purchase            --      Repaid
Xugang Wang                  163      Advance: material purchase            --      Repaid
Gaishi Wang                  117      Advance: material purchase            --      Repaid
Penghui Fan                1,232      Advance: material purchase            --      Repaid
Yushan Li                    479      Advance: business trip                --      Repaid
Naihui Wang               92,156      Advance: material purchase            --      Repaid
Guochao Zhi                  298      Advance: business trip                --      Repaid
Xi'an Runfeng Investing  243,249      Advance: business trip                --      Repaid
Yonghong Ma               16,030      Advance: business trip                --      Repaid
Guozhen Shang              1,141      Advance: business trip                --      Repaid
Shengwei Miao            250,378      Advance: business trip                --      Repaid
</TABLE>

      The majority of these borrowings and short term loans are actually
advances to employees during the normal course of business. It is a normal
practice for Chinese companies to advance funds to employees for company
business purposes. Employees might have to travel throughout different provinces
in China to carry out their duties and from time to time, they need to pay on
behalf of the company (e.g. travel expenses, accommodations, entertainment or
make purchases for the Company). However, there is no widely accepted company
credit card system in much of China and therefore, the Company will advance
funds to employees for such purposes.

            Stockholders had also advanced funds totaling $193,433 and $32,772
to the Company as of December 31, 2004 and 2003 respectively as short-term,
unsecured loans free of interest payment.

      The breakdown of the shareholders who advanced loans to our Company as of
December 31, 2003 and 2004 is as follows:

As of December 31, 2004

<TABLE>
<CAPTION>
Name of individual              Amount      Business purpose         Balance as of June      Payment terms
                                                                               13, 2005
--------------------------------------------------------------------------------------------------------------
<S>                             <C>         <C>                                  <C>         <C>
Kangrang Ma                     15,991      Temporary borrowing                  15,991      July 2005
Heng Li                         10,976      Temporary borrowing                  10,976      End of June 2005
Xi'an Runfeng Investing            163      Temporary borrowing                     163      August 2005
</TABLE>

As of December 31, 2003

<TABLE>
<CAPTION>
Name of individual              Amount      Business purpose         Balance as of June      Payment terms
                                                                               13, 2005
--------------------------------------------------------------------------------------------------------------
<S>                              <C>        <C>                                      <C>     <C>
Kangrang Ma                      9,079      Temporary borrowing                      --      Paid
</TABLE>

            The Company issued a Convertible Promissory Note of $1,900,000 to
the shareholders of Northwest; the Promissory Note is convertible in the
Company's sole discretion into 10,465,725 (post a one for eighteen reverse split
and provided that such reverse split has occured) shares to exchange for 70% of
the outstanding shares of Northwest. The Promissory Note is due on June 30, 2005
and accrues interest at the rate of 5% per annum.

<PAGE>

ITEM 13. EXHIBITS

3.1.  Articles of Incorporation (1) 3.2 By Laws (1)

3.3   Certificate of Amendment to Articles of Incorporation

10.1  Stock Purchase Agreement dated as of December 20, 2004 by and among Art
      Malone, Jr., Zhi Lan Wang and Jun Lin (2)

10.2  Agreement and Plan of Reorganization dated as of December 20, 2004 by and
      among Secured Data, Inc., Northwest Bio-Technic Inc., and the shareholders
      of Northwest Bio- Technic Inc.; and Convertible Promissory Note (2)

31.1  Sarbanes Oxley Section 302 Certification of Chief Executive Officer

31.2  Sarbanes Oxley Section 302 Certification of Chief Financial Officer

32.1  Sarbanes Oxley Section 906 Certification of Chief Executive Officer

32.2  Sarbanes Oxley Section 906 Certification of Chief Financial Officer

99.1  Code of Ethics

(1) Incorporated by reference from the registration statement on form SB-2 filed
on or about July 28, 2000.

(2) Incorporated by reference from the current report on form 8-K filed on or
about December 27, 2004.

ITEM 14. PRINCIPAL ACCOUNTING FEES AND SERVICES

AUDIT FEES

      The aggregate fees billed for each of the last two fiscal years for
professional services rendered by the principal accountant for our audit of
annual financial statements and review of financial statements included in our
Form 10-KSBs and 10-QSBs or services that are normally provided by the
accountant in connection with statutory and regulatory filings or engagements
for those fiscal years was:

2004: $ 20,000  - Jimmy C. H. Cheung & Co.

2003: $ 5,000   - Epstein, Weber & Conover, PLC

AUDIT-RELATED FEES

For fiscal 2004 and 2003, the Company's auditors did not bill any fees for
assurance and related services that are reasonably related to the performance of
the audit or review of the Company's financial statements and are not reported
under "Audit Fees" above.

TAX FEES

No fees were billed by the Company's auditors for professional services for tax
compliance, tax advice, and tax planning for fiscal 2004 and 2003, respectively.

ALL OTHER FEES

      The aggregate fees billed in each of the last two fiscal years for the
products and services provided by the principal accountant, other than the
services reported in paragraph (1) was:

2004: $0        - Jimmy C. H. Cheung & Co.

2003: $3,350    - Epstein, Weber & Conover, PLC

<PAGE>

AUDIT COMMITTEE

The Company's Board of Directors acts as its audit committee, and it meets prior
to filing of any Form 10-QSB or 10-KSB to approve those filings. In addition,
the committee meets to discuss audit plans and anticipated fees for audit and
tax work prior to the commencement of that work. Approximately 100% of all fees
paid to our independent auditors for fiscal 2004 are pre-approved by the audit
committee.

<PAGE>

                                   SIGNATURES

         Pursuant to the requirements of Section 13 or 15(d) of the Securities
and Exchange Act, the Registrant has duly caused this Report to be signed on its
behalf by the undersigned thereunto duly authorized.


Date: June 17, 2005                             By: /s/ Jingan Wang
                                                    Chief Executive Officer

      Pursuant to the requirements of the Securities and Exchange Act of 1934,
this Report has been signed below by the following person on behalf of the
Registrant and in the capacities and on the dates indicated.

SIGNATURE             TITLE                                        DATE
---------             -----                                        ----


/s/ Jingan Wang       Chairman and Chief Executive Officer         June 17, 2005
                      (Principal Executive Officer)


/s/ Sanding Tao       Chief Financial Officer (Principal           June 17, 2005
                      Financial Officer)

/s/ Xinwen Hou        Secretary, Director                          June 17, 2005

<PAGE>

                               SECURED DATA, INC.
                                AND SUBSIDIARIES
                              FINANCIAL STATEMENTS
               AS OF DECEMBER 31, 2004 (CONSOLIDATED AND RESTATED)

<PAGE>

                       SECURED DATA, INC. AND SUBSIDIARIES

                                    CONTENTS

<TABLE>
<CAPTION>
                                                                                                        Pages
--------------------------------------------------------------------------------------------------------------
<S>                                                                                                     <C>
Report of Independent Registered Public Accounting Firm                                                      1
--------------------------------------------------------------------------------------------------------------

Balance Sheet as of December 31, 2004 (Consolidated and Restated)                                            2
--------------------------------------------------------------------------------------------------------------

Statements of Operations and Comprehensive loss for the years ended December 31, 2004 (Consolidated and
Restated) and 2003                                                                                           3
--------------------------------------------------------------------------------------------------------------

Statements of Stockholders' Equity for the years ended December 31, 2004 (Consolidated and Restated)
and 2003                                                                                                     4
--------------------------------------------------------------------------------------------------------------

Statements of Cash Flows for the years ended December 31, 2004 (Consolidated and Restated) and 2003          5
--------------------------------------------------------------------------------------------------------------

Notes to Consolidated Financial Statements as of December 31, 2004 (Restated)                           6 - 14
--------------------------------------------------------------------------------------------------------------
</TABLE>

<PAGE>

[LOGO]  Jimmy C.H. Cheung & Co
        Certified Public Accountants
        (A member of Kreston International)

REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

To the Board of Directors of:
Secured Data, Inc. and Subsidiaries

We have audited the accompanying balance sheet of Secured Data, Inc. and
subsidiaries as of December 31, 2004 (consolidated) and the related statements
of operations and comprehensive loss, changes in stockholders' equity and cash
flows for the years ended December 31, 2004 (consolidated) and 2003. These
financial statements are the responsibility of the Company's management. Our
responsibility is to express an opinion on these financial statements based on
our audits.

We conducted our audits in accordance with the standards of the Public Company
Accounting Oversight Board (United States). Those standards require that we plan
and perform the audits to obtain reasonable assurance about whether the
financial statements are free of material misstatement. An audit includes
examining, on a test basis, evidence supporting the amounts and disclosures in
the financial statements. An audit also includes assessing the accounting
principles used and significant estimates made by management, as well as
evaluating the overall financial statement presentation. We believe that our
audits of the financial statements provide a reasonable basis for our opinion.

In our opinion, the financial statements referred to above present fairly, in
all material respects, the financial position of Secured Data, Inc. and
subsidiaries, as of December 31, 2004 (consolidated and restated), and the
results of its operations and its cash flows for the years ended December 31,
2004 (consolidated and restated) and 2003, in conformity with accounting
principles generally accepted in the United States of America.

As discussed in Note 2, the accompanying consolidated financial statements for
the year ended December 31, 2004 have been restated.

The accompanying consolidated financial statements have been prepared assuming
that the Company will continue as a going concern. As discussed in Note 14 to
the consolidated financial statements, the Company had a net loss of $219,730,
an accumulated deficit of $2,034,098 and a working capital deficiency of
$342,854 and used cash in operations of $526,363. These factors raise
substantial doubt about its ability to continue as a going concern. Management's
plans concerning this matter are also described in Note 14. The accompanying
consolidated financial statements do not include any adjustments that might
result from the outcome of this uncertainty.


JIMMY C.H. CHEUNG & CO
Certified Public Accountants

Hong Kong

Date: April 11, 2005 except for Note 2, to which the date is June 17, 2005.

         304 Dominion Centre, 43 Queen's Road East, Wanchai, Hong Kong    [LOGO]
 Tel: (852) 25295500 Fax: (852) 28651067 Email: jchc@krestoninternational.com.hk
                      Website: http://www.jimmycheungco.com


                                                                               1
<PAGE>

                       SECURED DATA, INC. AND SUBSIDIARIES
                                  BALANCE SHEET
               AS OF DECEMBER 31, 2004 (CONSOLIDATED AND RESTATED)

<TABLE>
<CAPTION>
                                     ASSETS
                                                                                    2004
                                                                           (As Restated)
                                                                         ---------------
<S>                                                                      <C>
CURRENT ASSETS
    Cash and cash equivalents                                            $       167,511
    Accounts receivable, net of allowances                                       104,144
    Inventories, net                                                           1,302,025
    Due from stockholders                                                         62,493
    Other assets                                                                 335,058
                                                                         ---------------
        Total Current Assets                                                   1,971,231

PROPERTY AND EQUIPMENT, NET                                                      879,503

LAND USE RIGHTS, NET                                                             133,974

OTHER ASSETS
    Investment in affiliate                                                       31,190
                                                                         ---------------
TOTAL ASSETS                                                             $     3,015,898
                                                                         ===============

                      LIABILITIES AND STOCKHOLDERS' EQUITY

CURRENT LIABILITIES
    Accounts payable                                                     $        56,454
    Other payables and accrued expenses                                          145,191
    Value added tax payables                                                      12,323
    Income tax and other tax payables                                              6,684
    Convertible note payable                                                   1,900,000
    Due to stockholders                                                          193,433
                                                                         ---------------
        Total Current Liabilities                                              2,314,085
                                                                         ---------------

COMMITMENTS AND CONTINGENCIES                                                         --

MINORITY INTEREST                                                                 58,915
                                                                         ---------------

STOCKHOLDERS' EQUITY
    Preferred stock, $0.001 par value, 5,000,000 shares authorized,
        none issued and outstanding                                                   --
    Common stock, $0.001 par value, 100,000,000 shares authorized,
        93,604,958 shares issued and outstanding                                  93,605
    Additional paid-in capital                                                 2,583,391
    Retained earnings (deficit)
      Unappropriated                                                          (2,041,348)
      Appropriated                                                                 7,250
                                                                         ---------------
        Total Stockholders' Equity                                               642,898
                                                                         ---------------

TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY                               $     3,015,898
                                                                         ---------------
</TABLE>

    The accompanying notes are an integral part of these financial statements


                                                                               2
<PAGE>

                       SECURED DATA, INC. AND SUBSIDIARIES
                 STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS
   FOR THE YEARS ENDED DECEMBER 31, 2004 (CONSOLIDATED AND RESTATED) AND 2003

<TABLE>
<CAPTION>
                                                                                 2004
                                                                       (Consolidated)
                                                                        (As Restated)                 2003
                                                                      ---------------      ---------------
<S>                                                                   <C>                  <C>
NET SALES                                                             $     2,478,763      $       715,859

COST OF SALES                                                              (2,235,189)            (683,430)
                                                                      ---------------      ---------------

GROSS PROFIT                                                                  243,574               32,429
                                                                      ---------------      ---------------

OPERATING EXPENSES
    Selling expenses and distribution expenses                                 41,569               49,833
    General and administrative expenses                                       415,342               41,729
    Depreciation and amortization                                               9,012                5,543
                                                                      ---------------      ---------------
           Total Operating Expenses                                           465,923               97,105
                                                                      ---------------      ---------------

LOSS FROM OPERATIONS                                                         (222,349)             (64,676)

OTHER INCOME (EXPENSES)
    Equity in loss of affiliate                                                  (211)                  --
    Interest income, net                                                        1,260               51,762
    Other income, net                                                             711                  272
                                                                      ---------------      ---------------
           Total Other Income                                                   1,760               52,034

                                                                      ---------------      ---------------
LOSS FROM OPERATIONS BEFORE TAXES AND MINORITY INTEREST                      (220,589)             (12,642)

INCOME TAX EXPENSE                                                             (7,503)                  --

MINORITY INTEREST                                                               8,362                6,606
                                                                      ---------------      ---------------

NET LOSS                                                                     (219,730)              (6,036)

OTHER COMPREHENSIVE  LOSS
    Foreign currency translation loss                                              --                   --
                                                                      ---------------      ---------------

COMPREHENSIVE LOSS                                                    $      (219,730)     $        (6,036)
                                                                      ===============      ===============

Net loss per share-basic and diluted                                  $        (0.003)     $            --
                                                                      ===============      ===============

Weighted average number of shares outstanding during the year-
    basic and diluted                                                      81,123,434           80,735,590
                                                                      ===============      ===============
</TABLE>

    The accompanying notes are an integral part of these financial statements

                                                                               3
<PAGE>

                       SECURED DATA, INC. AND SUBSIDIARIES
                       STATEMENTS OF STOCKHOLDERS' EQUITY
   FOR THE YEARS ENDED DECEMBER 31, 2004 (CONSOLIDATED AND RESTATED) AND 2003

<TABLE>
<CAPTION>
                                                                                                Additional
                                         Preferred Stock               Common Stock                paid-in
                                      Shares        Amount         Shares         Amount           capital
                                    ----------    -----------    -----------    -----------    -----------
<S>                                         <C>   <C>             <C>           <C>            <C>
Balance at January 1, 2003                        $        --     80,735,590    $    80,736    $ 4,446,260

Net loss for the year                                      --                            --             --
                                    ----------    -----------    -----------    -----------    -----------
Balance at December 31, 2003                --             --     80,735,590         80,736      4,446,260

Stock issued in recapitalization                           --     12,869,368         12,869       (465,640)

Recapitalization                                           --             --             --     (1,397,229)

Net loss for the year                                      --                            --             --

Transfer to statutory and staff
     welfare reserves                                      --                            --             --
                                    ----------    -----------    -----------    -----------    -----------
Balance at December 31, 2004
(consolidated)                              --    $        --     93,604,958    $    93,605    $ 2,583,391
                                    ==========    ===========    ===========    ===========    ===========

<CAPTION>
                                    Unappropriated    Appropriated
                                          retained        retained
                                           deficit        earnings          Total
                                       -----------     -----------    -----------
<S>                                    <C>             <C>                <C>
Balance at January 1, 2003             $(1,808,415)    $        83      2,718,664

Net loss for the year                       (6,036)             --         (6,036)
                                       -----------     -----------    -----------
Balance at December 31, 2003            (1,814,451)             83      2,712,628

Stock issued in recapitalization        (1,397,229)             --     (1,850,000)

Recapitalization                         1,397,229              --             --

Net loss for the year                     (219,730)             --       (219,730)

Transfer to statutory and staff
     welfare reserves                       (7,167)          7,167             --
                                       -----------     -----------    -----------
Balance at December 31, 2004
(consolidated)                         $(2,041,348)    $     7,250        642,898
                                       ===========     ===========    ===========
</TABLE>

    The accompanying notes are an integral part of these financial statements


                                                                               4
<PAGE>

                       SECURED DATA, INC. AND SUBSIDIARIES
                            STATEMENTS OF CASH FLOWS
   FOR THE YEARS ENDED DECEMBER 31, 2004 (CONSOLIDATED AND RESTATED) AND 2003

<TABLE>
<CAPTION>
                                                                                           2004
                                                                                 (Consolidated)
                                                                                  (As Restated)                2003
                                                                                ---------------     ---------------
<S>                                                                             <C>                 <C>
CASH FLOWS FROM OPERATING ACTIVITIES
     Net loss                                                                   $      (219,730)    $        (6,036)
     Adjusted to reconcile net loss to cash provided
         by (used in) operating activities:
         Depreciation and amortization - cost of sales                                   85,085              72,185
         Depreciation and amortization                                                    9,012                  --
         Equity in loss of affiliate                                                        211                  --
         Minority interest                                                               (8,362)             (6,606)
     Changes in operating assets and liabilities (Increase) decrease in:
         Accounts receivable, net                                                       122,023            (178,863)
         Inventories, net                                                              (405,019)            319,450
         Other receivables                                                             (236,920)            (69,131)
         Increase (decrease) in:
         Accounts payable                                                                 7,194             (15,876)
         Other payables and accrued expenses                                            101,234             (24,423)
         Value added tax payables                                                        12,323                  --
         Income tax and other taxes payable                                               6,586                  --
                                                                                ---------------     ---------------
         Net cash (used in) provided by operating activities                           (526,363)             90,700
                                                                                ---------------     ---------------

CASH FLOWS FROM INVESTING ACTIVITIES
     Decrease in notes receivable                                                       506,774                  --
     Purchase of property and equipment                                                (305,070)            (19,134)
     Investment in affiliate                                                            (31,401)                 --
     Acquisition of land use rights                                                    (134,661)                 --
                                                                                ---------------     ---------------
         Net cash provided by (used in) investing activities                             35,642             (19,134)
                                                                                ---------------     ---------------

CASH FLOWS FROM FINANCING ACTIVITIES
     (Decrease) increase in note payable                                               (241,642)             59,806
     Decrease (increase) in due from stockholders                                       569,717            (133,421)
     Contribution by the stockholders                                                    50,000                  --
     Increase (decrease) in due to stockholders                                         184,354             (99,317)
                                                                                ---------------     ---------------
         Net cash provided by (used in) financing activities                            562,429            (172,932)
                                                                                ---------------     ---------------

NET INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS                                     71,708            (101,366)

CASH AND CASH EQUIVALENTS AT BEGINNING OF YEAR                                           95,803             197,169
                                                                                ---------------     ---------------

CASH AND CASH EQUIVALENTS AT END OF YEAR                                        $       167,511     $        95,803
                                                                                ---------------     ---------------

SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION

Cash paid during the year for:
     Income taxes                                                               $        (7,503)    $            --
                                                                                ===============     ===============

     Interest expenses                                                          $            --     $        (2,152)
                                                                                ===============     ===============
</TABLE>

SUPPLEMENTAL DISCLOSURE OF NON-CASH INVESTING AND FINANCING ACTIVITIES:

During 2004, the Company issued 80,735,590 shares of common stock for 30% of the
common stock of Northwest.

During 2004, the Company issued a Convertible Promissory Note of $1,900,000 for
70% of the common stock of Northwest.

    The accompanying notes are an integral part of these financial statements


                                                                               5
<PAGE>

                       SECURED DATA, INC. AND SUBSIDIARIES
                        NOTES TO THE FINANCIAL STATEMENTS
               AS OF DECEMBER 31, 2004 (CONSOLIDATED AND RESTATED)

1.    SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND ORGANIZATION

      (A)   Organization

            Secured Data, Inc. ("Secured Data") is a US listed company which was
            incorporated in Nevada on March 16, 2000 under the name Enternet,
            Inc. On May 23, 2002, the Articles of Incorporation were amended to
            change the name of the Company to Secured Data, Inc.

            Northwest Bio-Technic Inc. ("Northwest") was incorporated in the
            British Virgin Islands ("BVI") on June 25, 2004. Xian Huifeng
            Biochemistry Joint-Stock Company Limited ("Huifeng Biochemistry")
            was incorporated in the People's Republic of China ("PRC") on
            January 20, 2000 as a company with limited liabilities and was
            restructured as a joint stock company on September 29, 2002 under
            the laws of the PRC.

            Huifeng Biochemistry produces plant extracts and bio-chemical
            products used as pharmaceutical raw materials in the PRC. Most of
            its products are distributed within the PRC and some European
            countries.

            On August 23, 2001, Huifeng Biochemistry established a 70% owned
            subsidiary, Xian Huifeng Biochemistry Engineering Company Limited
            ("Huifeng Engineering") in the PRC with a registered capital of
            $265,778. The subsidiary has no operations since its incorporation.

            On June 16, 2004 Huifeng Biochemistry acquired an 86.7% interest in
            Baoji Jinsen Pharmaceutical Company Limited, later renamed to Xian
            Huifeng Pharmaceutical Company Limited ("Huifeng Pharmaceutical"), a
            limited liability company in the PRC. On November 10, 2004 Huifeng
            Pharmaceutical increased its registered capital from $181,159 to
            $603,865. The increased registered capital was fully subscribed by a
            stockholder of the Company, diluting the Company's interest in
            Huifeng Pharmaceutical from 86.7% to 26%.

            During 2004, Huifeng Biochemistry's shareholders exchanged 100% of
            their ownership of Huifeng Biochemistry for 500,000 shares of
            Northwest under a reorganization plan. The transfer has been
            accounted for as a reorganization of entities under common control
            as the companies were beneficially owned by principally identical
            shareholders and share common management.

            On December 20, 2004, pursuant to a Stock Purchase Agreement, a
            Secured Data shareholder sold 7,229,601 shares in Secured Data to
            two Northwest shareholders for $300,000. On the same date, Secured
            Data entered into an Agreement and Plan of Reorganization with the
            shareholders of Northwest to exchange 30% of Northwest's outstanding
            shares for 80,735,590 shares of Secured Data. In addition, the
            Agreement calls for Secured Data to issue a Convertible Promissory
            Note for $1,900,000 that is convertible into 10,465,725 (post a one
            for eighteen reverse split) shares of Secured Data for the remaining
            70% of Northwest. As of April 11, 2005, the Convertible Note has not
            been exercised.

            The merger of Secured Data and Northwest has been recorded as a
            recapitalization by Northwest, with Northwest being treated as the
            continuing entity. The financial statements have been prepared as if
            the reorganization had occurred retroactively. Secured Data,
            Northwest, Huifeng Biochemistry and Huifeng Engineering are
            hereafter referred to as (the "Company"). The transactions were
            treated for accounting purposes as a capital transaction and
            recapitalization by the accounting acquirer ("Northwest") and as a
            reorganization by the accounting acquiree ("Secured Data").

            Accordingly, the financial statements include the following:

            (1)   The balance sheet consists of the net assets of the acquirer
                  at historical cost and the net assets of the acquiree at
                  historical cost.

            (2)   The statement of operations includes the operations of the
                  acquirer for the periods presented and the operations of the
                  acquiree from the date of the merger.


                                                                               6
<PAGE>

                       SECURED DATA, INC. AND SUBSIDIARIES
                        NOTES TO THE FINANCIAL STATEMENTS
               AS OF DECEMBER 31, 2004 (CONSOLIDATED AND RESTATED)

1.    SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND ORGANIZATION (CONTINUED)

      (B)   Use of estimates

            The preparation of the financial statements in conformity with
            generally accepted accounting principles requires management to make
            estimates and assumptions that affect the reported amount of assets
            and liabilities and disclosure of contingent assets and liabilities
            at the date of the financial statements and the reported amounts of
            revenues and expenses during the reporting period. Actual results
            could differ from those estimates.

      (C)   Principles of consolidation

            The accompanying 2004 consolidated financial statements include the
            accounts of Secured Data and its 100% owned subsidiary Northwest,
            100% owned subsidiary Huifeng Biochemistry, 70% owned subsidiary
            Huifeng Engineering and 86.7% owned subsidiary Huifeng
            Pharmaceutical from the date of its acquisition on June 16, 2004 to
            the date of its dilution in November 10, 2004. The Company accounts
            for its investment in Huifeng Pharmaceutical from November 11, 2004
            to December 31, 2004 under the equity method of accounting. The
            accompanying 2003 financial statements include the accounts of
            Huifeng Biochemistry and its 70% owned subsidiary Huifeng
            Engineering. Minority interest represents the minority shareholders'
            proportionate share of Huifeng Engineering and Huifeng
            Pharmaceutical. All significant inter-company balances and
            transactions have been eliminated in consolidation.

      (D)   Cash and cash equivalents

            For purpose of the statements of cash flows, cash and cash
            equivalents include cash on hand and demand deposits with a bank
            with a maturity of three months or less.

      (E)   Accounts receivable

            The Company extends unsecured credit to its customers in the
            ordinary course of business but mitigates the associated risks by
            performing credit checks and actively pursuing past due accounts. An
            allowance for doubtful accounts is established and recorded based on
            managements' assessment of the credit history with the customer and
            current relationships with them. As of December 31, 2004 the Company
            considers all its accounts receivable to be collectable and no
            provision for doubtful accounts has been made in the financial
            statements.

      (F)   Inventories

            Inventories are stated at the lower of cost or market value, cost
            being determined on a first in, first out method. The Company
            provides for inventory allowances based on excess and obsolete
            inventories determined principally by customer demand.

      (G)   Property and equipment

            Property and equipment are stated at cost, less accumulated
            depreciation. Expenditures for additions, major renewals and
            betterments are capitalized and expenditures for maintenance and
            repairs are charged to expense as incurred.

            Depreciation is provided on a straight-line basis, less estimated
            residual value over the assets' estimated useful lives. The
            estimated useful lives are as follows:

            Plant and machinery                        10 Years
            Motor vehicles                             10 Years
            Furniture, fixtures and equipment            5 Years

            Land use rights are stated at cost, less accumulated amortization.
            The land use rights are amortized over the term of the relevant
            rights of 50 years from the date of acquisition.


                                                                               7
<PAGE>

                       SECURED DATA, INC. AND SUBSIDIARIES
                        NOTES TO THE FINANCIAL STATEMENTS
               AS OF DECEMBER 31, 2004 (CONSOLIDATED AND RESTATED)

1.    SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND ORGANIZATION (CONTINUED)

      (H)   Long-lived assets

            The Company accounts for long-lived assets under the Statements of
            Financial Accounting Standards Nos. 142 and 144 "Accounting for
            Goodwill and Other Intangible Assets" and "Accounting for Impairment
            or Disposal of Long-Lived Assets" ("SFAS No. 142 and 144"). In
            accordance with SFAS No. 142 and 144, long-lived assets, goodwill
            and certain identifiable intangible assets held and used by the
            Company are reviewed for impairment whenever events or changes in
            circumstances indicate that the carrying amount of an asset may not
            be recoverable. For purposes of evaluating the recoverability of
            long-lived assets, when undiscounted future cash flows will not be
            sufficient to recover an asset's carrying amount, the asset is
            written down to its fair value.

      (I)   Fair value of financial instruments

            Statement of Financial Accounting Standards No. 107, "Disclosure
            About Fair Value of Financial Instruments," requires certain
            disclosures regarding the fair value of financial instruments. Trade
            accounts receivable, accounts payable, and accrued liabilities are
            reflected in the financial statements at fair value because of the
            short-term maturity of the instruments.

      (J)   Revenue recognition

            The Company recognizes revenue upon delivery or shipment of the
            products, at which time title passes to the customer provided that:
            there are no uncertainties regarding customer acceptance; persuasive
            evidence of an arrangement exists; the sales price is fixed or
            determinable; and collectability is deemed probable.

      (K)   Income taxes

            The Company accounts for income taxes under the Statement of
            Financial Accounting Standards No. 109, "Accounting for Income
            Taxes" ("Statement 109"). Under Statement 109, deferred tax assets
            and liabilities are recognized fort the future tax consequences
            attributable to differences between the financial statement carrying
            amounts of existing assets and liabilities and their respective tax
            bases. Deferred tax assets and liabilities are measured using
            enacted tax rates expected to apply to taxable income in the years
            in which those temporary differences are expected to be recovered or
            settled. Under Statement 109, the effect on deferred tax assets and
            liabilities of a change in tax rates is recognized in income in the
            period that included the enactment date.

            PRC income tax is computed according to the relevant laws and
            regulations in the PRC. The Company's subsidiaries being registered
            as a new and high technology enterprise is entitled to an income tax
            reduction. According to the document of reductions approved by the
            local tax bureau, the income tax rate was reduced from 33% to 15% on
            a permanent basis. The income tax expenses for 2004 and 2003 were
            $7,503 and $0 respectively.

      (L)   Foreign currency translation

            The functional currency of the Company is the Chinese Renminbi
            ("RMB"). Transactions denominated in currencies other than RMB are
            translated into United States dollars using year end exchange rates
            as to assets and liabilities and average exchange rates as to
            revenues and expenses. Capital accounts are translated at their
            historical exchange rates when the capital transaction occurred. Net
            gains and losses resulting from foreign exchange translations are
            included in the statements of operations and stockholder's equity as
            other comprehensive income (loss). Cumulative translation adjustment
            amounts were insignificant at and for the years ended December 31,
            2004 and 2003 as the RMB is pegged to the United States dollar.


                                                                               8
<PAGE>

                       SECURED DATA, INC. AND SUBSIDIARIES
                        NOTES TO THE FINANCIAL STATEMENTS
               AS OF DECEMBER 31, 2004 (CONSOLIDATED AND RESTATED)

1.    SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND ORGANIZATION (CONTINUED)

      (M)   Comprehensive loss

            The foreign currency translation gain or loss resulting from
            translation of the financial statements expressed in RMB to United
            States Dollar is reported as other comprehensive loss in the
            statements of operations and stockholders' equity. Cumulative
            translation adjustment amounts were insignificant at and for the
            years ended December 31, 2004 and 2003.

      (N)   Loss per share

            Basic loss per share is computed by dividing loss available to
            common shareholders by the weighted average number of common shares
            outstanding during the period. Diluted income per share is computed
            similar to basic loss per share except that the denominator is
            increased to include the number of additional common shares that
            would have been outstanding if the potential common shares had been
            issued and if the additional common shares were dilutive.

            The weighted average number of shares used to compute the basic and
            diluted loss per share in these financial statements would
            potentially be further diluted in the future had the convertible
            promissory note of $1,900,000 (note 9) be exercised.

      (O)   Segments

            The Company operates in only one segment, thereafter segment
            disclosure is not presented.

      (P)   Recent Accounting Pronouncements

            Statement of Financial Accounting Standards ("SFAS") No. 151,
            "Inventory Costs - an amendment of ARB No. 43, Chapter 4 SFAS No.
            152, "Accounting for Real Estate Time-Sharing Transactions - an
            amendment of FASB Statements No. 66 and 67," SFAS No. 153,
            "Exchanges of Non-monetary Assets - an amendment of APB Opinion No.
            29," and SFAS No. 123 (revised 2004), "Share-Based Payment," were
            recently issued. SFAS No. 151, 152, 153 and 123 (revised 2004) have
            no current applicability to the Company and have no effect on the
            financial statements.


                                                                               9
<PAGE>

                       SECURED DATA, INC. AND SUBSIDIARIES
                        NOTES TO THE FINANCIAL STATEMENTS
               AS OF DECEMBER 31, 2004 (CONSOLIDATED AND RESTATED)

2.    RESTATEMENT OF FINANCIAL STATEMENTS

      The Company originally recorded during the year ended December 31, 2004,
      the costs incurred by SCRE prior to the reverse merger as expenses of the
      Company for that year. Under reverse merger accounting such costs should
      be treated as a reduction of additional paid in capital. The Company has
      restated these costs in the Balance Sheet, Statement of Operations,
      Statement of Stockholders' Equity and the Statement of Cash Flows.

      A summary of significant effects of the restatement is as follows:

<TABLE>
<CAPTION>
                                                             December 31,
                                                                     2004         December 31,
                                                           (As Previously                 2004
      Statement of Operations                                   Reported)        (As Restated)
                                                           --------------       --------------
      <S>                                                  <C>                  <C>
      Net sales                                            $    2,478,763       $    2,478,763
      Cost of sales                                            (2,235,189)          (2,235,189)
      Gross profit                                                243,574              243,574
      Operating expenses                                          964,637              465,923
      Loss from operations                                       (721,063)            (222,349)
      Other income (expenses)                                       1,760                1,760
      Income tax expense                                           (7,503)              (7,503)
      Minority interest                                             8,362                8,362
      Net loss                                                   (718,444)            (219,730)
      Net loss per share-basic and diluted                 $        (0.01)      $       (0.003)
      Weighted average number of shares outstanding
           during the year-basic and diluted                   81,123,434           81,123,434

      <CAPTION>
                                                             December 31,
                                                                     2004         December 31,
                                                           (As Previously                 2004
      Balance sheet                                             Reported)        (As Restated)
                                                           --------------       --------------
      <S>                                                  <C>                  <C>
      Current liabilities                                  $    1,971,231       $    1,971,231
      Property and equipment, net                                 879,503              879,503
      Land use rights, net                                        133,974              133,974
      Other assets                                                 31,190               31,190
      Total assets                                              3,015,898            3,015,898
      Current liabilities                                       2,314,085            2,314,085
      Minority interest                                            58,915               58,915
      Stockholders' equity
           Common stock                                            93,605               93,605
           Additional paid-in capital                           3,082,105            2,583,391
           Retained earnings (deficit)
             Unappropriated                                    (2,540,062)          (2,041,348)
             Appropriated                                           7,250                7,250
      Total liabilities and stockholders' equity           $    3,015,898       $    3,015,898
</TABLE>

3.    ACCOUNTS RECEIVABLE

      Accounts receivable at December 31, 2004 consisted of the following:

                                                                            2004
                                                                        --------

      Accounts receivable                                               $104,144
      Less: allowance for doubtful accounts                                   --
                                                                        --------
      Accounts receivable, net                                          $104,144
                                                                        ========

      As of December 31, 2004 and 2003, the Company considered all accounts
      receivable collectable and has not recorded a provision for doubtful
      accounts. SECURED DATA, INC. AND SUBSIDIARIES NOTES TO THE FINANCIAL
      STATEMENTS AS OF DECEMBER 31, 2004 (CONSOLIDATED AND RESTATED)


                                                                              10
<PAGE>

                       SECURED DATA, INC. AND SUBSIDIARIES
                        NOTES TO THE FINANCIAL STATEMENTS
               AS OF DECEMBER 31, 2004 (CONSOLIDATED AND RESTATED)

4.    INVENTORIES

      Inventories at December 31, 2004 consisted of the following:

                                                                      2004
                                                                ----------

      Raw materials                                             $1,047,781
      Work-in-progress                                              11,917
      Finished goods                                               242,327
                                                                ----------
                                                                 1,302,025
      Less: provision of obsolescence                                   --
                                                                ----------
                                                                $1,302,025
                                                                ==========

      For the year ended December 31, 2004 and 2003, the Company did not have
      any obsolete inventories.

5.    OTHER ASSETS

      Other assets at December 31, 2004 consisted of the following:

                                                                      2004
                                                                  --------

      Short-term note receivable                                  $181,159
      Advances to staff                                             39,227
      Prepayments                                                   63,018
      Trade deposits paid                                           32,590
      Other                                                         19,064
                                                                  --------
                                                                  $335,058
                                                                  ========

6.    PROPERTY AND EQUIPMENT

      The following is a summary of property and equipment at December 31, 2004:

                                                                      2004
                                                                ----------

      Plant and machinery                                       $  769,476
      Motor vehicles                                                87,262
      Furniture and office equipment                                20,251
      Construction in progress - factory building                  286,039
                                                                ----------
                                                                 1,163,028
      Less: accumulated depreciation                               283,525
                                                                ----------
      Property and equipment, net                               $  879,503
                                                                ==========

      Depreciation expenses for the years ended December 31, 2004 and 2003 were
      $93,411 and $72,185 respectively.

7.    INVESTMENT IN AFFILIATE

      On June 16, 2004, the Company's subsidiary Northwest Bio-Technic Inc.
      ("Northwest") acquired an 86.7% interest in Baoji Jinsen Pharmaceutical
      Company Limited, later renamed to Xian Huifeng Pharmaceutical Company
      Limited ("Huifeng Pharmaceutical"), which owns licenses to manufacture two
      pharmaceutical products in the PRC. The balance of 13.3% is held by a
      stockholder of the Company. On November 10, 2004 Huifeng Pharmaceutical
      increased its registered capital from $181,159 to $603,865. The increased
      registered capital was fully subscribed by a stockholder of the Company,
      diluting the Company's interest in Huifeng Pharmaceutical from 86.7% to
      26%.


                                                                              11
<PAGE>

                       SECURED DATA, INC. AND SUBSIDIARIES
                        NOTES TO THE FINANCIAL STATEMENTS
               AS OF DECEMBER 31, 2004 (CONSOLIDATED AND RESTATED)

7.    INVESTMENT IN AFFILIATE (CONTINUED)

      A summary of the unaudited financial statements of the affiliate as of
      December 31, 2004 is as follows:

      Current assets                                            $ 425,641
      Non-current assets                                            1,086
                                                                ---------
      Total assets                                                426,727
                                                                =========
      Current liabilities                                           4,831
      Stockholders' equity                                        421,896
                                                                ---------
      Total liabilities and stockholders' equity                $ 426,727
                                                                =========
      Revenue                                                   $      --
                                                                =========
      Net loss from November 11, 2004 to December 31, 2004           (810)
                                                                =========

      The Company's share of the loss for 2004 :
      Company share at 26% and equity in loss of affiliate      $    (211)
                                                                =========

8.    OTHER PAYABLES AND ACCRUED EXPENSES

      Other payables and accrued liabilities at December 31, 2004 consist of the
      following:

                                                                      2004
                                                                  --------

      Other payables                                              $ 24,640
      Accrued expenses                                             113,599
      Deposits received from customers                               6,952
                                                                  --------
                                                                  $145,191
                                                                  ========

9.    CONVERTIBLE NOTE PAYABLE

      Note payable at December 31, 2004 consists of the following:

                                                                      2004
                                                                ----------

      Convertible Promissory Note                               $1,900,000
                                                                ==========

      Pursuant to a Convertible Promissory Note, the Company promises to pay to
      Shareholders or their registered assigns, the principal sum of $1,900,000
      on June 30, 2005 or such earlier date as the Convertible Note is required
      or permitted to be repaid as provided hereunder the maturity date, and to
      pay interest to the Holders on the aggregate unconverted and then
      outstanding principal amount of this Convertible Note at the rate of 5%
      per annum, payable on the maturity date as set forth herein. Interest
      shall be calculated on the basis of a 360 day year and shall accrue on the
      maturity date. On the maturity date, the Company may, in its sole
      discretion, pay the principal sum by issuing to the Holder 10,465,725
      shares of the Company's restricted common stock at $0.1815 per share,
      provided a required 1 for 18 reverse stock split of the common stock has
      been effected. As of April 11, 2005, the Convertible Promissory Note has
      not been exercised.

10.   COMMITMENTS AND CONTINGENCIES

      (A)   Employee benefits

            The full time employees of the Company are entitled to employee
            benefits including medical care, welfare subsidies, unemployment
            insurance and pension benefits through a Chinese government mandated
            multi-employer defined contribution plan. The Company is required to
            accrue for those benefits based on certain percentages of the
            employees' salaries and make contributions to the plans out of the
            amounts accrued for medical and pension benefits. The total
            provision and contributions made for such employee benefits was
            $3,607 and $4,508 for the years ended December 31, 2004 and 2003,
            respectively. The Chinese government is responsible for the medical
            benefits and the pension liability to be paid to these employees.


                                                                              12
<PAGE>

                       SECURED DATA, INC. AND SUBSIDIARIES
                        NOTES TO THE FINANCIAL STATEMENTS
               AS OF DECEMBER 31, 2004 (CONSOLIDATED AND RESTATED)

10.   COMMITMENTS AND CONTINGENCIES (CONTINUED)

      (B)   Commitments

            The Company occupies office space from a third party under an
            operating lease which expires on March 2006 at a quarterly rental of
            $3,080. Accordingly, for 2004 and 2003, the Company recognized
            rental expense for this space in the amount of $12,319 and $12,319,
            respectively.

            As of December 31, 2004, the Company has outstanding commitments
            with respect to non-cancelable operating leases, which are due as
            follows:

            2005                                             $12,319
            2006                                               3,080
                                                             -------
                                                             $15,399
                                                             =======

11.   SHAREHOLDERS' EQUITY

      (A)   Stock issuances

            On December 20, 2004 the Company entered into an Agreement and Plan
            of Reorganization with Northwest Bio-Technic Inc ("Northwest") to
            acquire 100% of Northwest equity. The Company issued 80,735,590
            shares in exchange for 30% of Northwest's outstanding shares.

            The Company has authorized up to 5,000,000 shares of preferred stock
            with a par value of $0.001 per share. The preferred stock can be
            issued in various series with varying dividend rates and
            preferences. At December 31, 2004 there are no issued series or
            shares of preferred stock.

      (B)   Appropriated retained earnings

            The Company's wholly owned subsidiary, Huifeng Biochemistry is
            required to make appropriations to reserves funds, comprising the
            statutory surplus reserve, statutory public welfare fund and
            discretionary surplus reserve, based on after-tax net income
            determined in accordance with generally accepted accounting
            principles of the People's Republic of China (the "PRC GAAP").
            Appropriation to the statutory surplus reserve should be at least
            10% of the after tax net income determined in accordance with the
            PRC GAAP until the reserve is equal to 50% of the entities'
            registered capital. Appropriations to the statutory public welfare
            fund are at 5% to 10% of the after tax net income determined in
            accordance with the PRC GAAP. The statutory public welfare fund is
            established for the purpose of providing employee facilities and
            other collective benefits to the employees and is non-distributable
            other than in liquidation. Appropriations to the discretionary
            surplus reserve are made at the discretion of the Board of
            Directors.

            During 2004 and 2003, the Company's wholly owned subsidiary Huifeng
            Biochemistry appropriated $7,167 and $83, respectively to the
            reserves funds based on its net income under PRC GAAP.

12.   RELATED PARTY TRANSACTIONS

      The Company had advanced funds totaling $62,493 and $632,210 to
      stockholders as of December 31, 2004 and 2003 respectively as short-term,
      unsecured loans free of interest payment.

      Stockholders had also advanced funds totaling $193,433 and $9,079 to the
      Company as of December 31, 2004 and 2003 respectively as short-term,
      unsecured loans free of interest payment.

      During 2004, the Company issued 6,232,290 shares of common stock having a
      fair value of $349,008 at $0.056 to a shareholder as repayment of cash
      advances of $373,937 to operate the Company's business. The Company
      recognized operating expenses of $373,937 as of December 31, 2004.

      The Company issued a Convertible Promissory Note of $1,900,000 to the
      shareholders of Northwest, the Note is convertible into 10,465,725 (post a
      one for eighteen reverse split) shares to exchange for 70% of the
      outstanding shares of Northwest.

      See Note 1 (A) for transactions with Northwest and its subsidiaries.


                                                                              13
<PAGE>

                       SECURED DATA, INC. AND SUBSIDIARIES
                        NOTES TO THE FINANCIAL STATEMENTS
               AS OF DECEMBER 31, 2004 (CONSOLIDATED AND RESTATED)

13.   CONCENTRATIONS AND RISKS

      During 2004 and 2003, 100% of the Company's assets were located in China
      and 90% of the Company's revenues were derived from companies located in
      China.

      The Company relied on two customers for approximately $790,217 and
      $802,324 respectively representing in aggregate 63% of sales for the year
      ended December 31, 2004, and three customers for approximately $78,865,
      $129,710 and 170,870 respectively representing in aggregate 58% of sales
      for the year ended December 31, 2003. At December 31, 2004 and 2003,
      accounts receivable from those customers totaled $32,119 and $149,814
      respectively.

      The Company also relied on four suppliers for approximately $443,718,
      $269,547, $288,832 and $339,895 respectively representing in aggregate 62%
      of purchases for the year ended December 31, 2004, and three suppliers for
      approximately $107,789, $146,781 and $148,827 respectively representing in
      aggregate 72% of purchases for the year ended December 31, 2003. At
      December 31, 2004 and 2003, accounts payable to those two suppliers
      totaled $1,182 and $41,472 respectively.

14.   GOING CONCERN

      As reflected in the accompanying consolidated financial statements, the
      Company has an accumulated deficit of $2,034,098 at December 31, 2004
      which includes a net loss of $219,730 for the year ended December 31,
      2004. The Company's current liabilities exceed its current assets by
      $342,854 and the Company used cash in operation of $526,363. These factors
      raise substantial doubt about its ability to continue as a going concern.
      In view of the matters described above, recoverability of a major portion
      of the recorded asset amounts shown in the accompanying consolidated
      balance sheet is dependent upon continued operations of the company, which
      in turn is dependent upon the Company's ability to raise additional
      capital, obtain financing and succeed in its future operations. The
      financial statements do not include any adjustments relating to the
      recoverability and classification of recorded asset amounts or amounts and
      classification of liabilities that might be necessary should the Company
      be unable to continue as a going concern.

      The Company is taking steps to increase its operating capacity and service
      providers to implement its business plan. Management believes that actions
      presently being taken to implement its business plan and generate revenues
      provide the opportunity for the Company to continue as a going concern.

15.   SUBSEQUENT EVENT

      On March 23, 2005 the Company's Board of Directors approved, subject to
      the approval of the Company's stockholders, an 18 for 1 reverse split of
      the Company's issued and outstanding common stock and an amendment to its
      Articles of Incorporation changing the name of the Company to "Huifeng
      Bio-pharmaceutical Technology Inc."


                                                                              14